Skip to main content

Table 6 Prediction of taxane-anthracycline sensitivity in patients with HER2-negative(HER2-) breast cancer

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

  pCR prediction(n = 488)
Prediction evaluation* PPV (SD) NPV (SD) Sensitivity (SD) Specificity (SD)
Unsupervised clustering     
BRmet50 93(14) 34(3) 58(3) 83(0.6)
PMID18271932Sig33 92(3) 32(5) 53(6) 83(6)
Anthracycline-taxane Centroid    
BRmet50 89(6) 27(0.6) 40(5) 83(6)
PMID18271932Sig33 77(4) 20(3) 29(1) 67(0.5)